SCHEMBL3927263

SCHEMBL3927263

CC(C)(C)OC(=O)[C@@H](O)C(N)Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.58
LAP3 P28838 4/20 0.57
ANPEP P15144 3/20 0.51
RNPEP Q9H4A4 1/20 0.51
DNPEP Q9ULA0 1/20 0.51
ITGA4 P13612 1/20 0.48
ITGB7 P26010 1/20 0.48
SLC15A1 P46059 1/20 0.48
SLC7A5 Q01650 2/20 0.47
ALPI P09923 1/20 0.46
PKM P14618 1/20 0.46
PTGS1 P23219 1/20 0.46
XIAP P98170 1/20 0.46
ATM Q13315 1/20 0.46
KLK5 Q9Y337 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CTSS P25774 2/20 0.44
CTSL P07711 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4659671 1.00 LTA4H (0.58) LTA4HLAP3ANPEPRNPEPDNPEP
SCHEMBL2848679 1.00 LTA4H (0.58) LTA4HLAP3ANPEPRNPEPDNPEP
SCHEMBL3915987 1.00 LTA4H (0.58) LTA4HLAP3ANPEPRNPEPDNPEP
SCHEMBL4730834 0.88 ITGA4 (0.48) LTA4HLAP3ANPEPITGA4ITGB7
SCHEMBL9052981 0.87 ITGA4 (0.45) LTA4HLAP3ANPEPRNPEPDNPEP
SCHEMBL11027685 0.85 SLC7A5 (0.46) LTA4HLAP3ANPEPRNPEPDNPEP
SCHEMBL8770458 0.85 LTA4H (0.46) LTA4HLAP3ANPEPRNPEPDNPEP
SCHEMBL5707507 0.85 METAP2 (0.58) LTA4HLAP3ANPEPITGA4ITGB7
SCHEMBL8144508 0.85 METAP2 (0.58) LTA4HLAP3ANPEPITGA4ITGB7
SCHEMBL6339522 0.84 LTA4H (0.77) LTA4HLAP3ANPEPRNPEPDNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed
US-5736517-A ADMINISTERING TO TREAT COLON, PROSTATE OR BREAST CANCER BIOMEASURE, INC. (US) 1998-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC LTA4H 1254/4885LAP3 2133/4885ANPEP 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.